Dr Broderick has a broad background in device development and product development in the DNA therapeutic and drug delivery field, with specific expertise in in vivo DNA vaccine animal studies and product development in relation to electroporation. Her particular area of focus is electroporation device design pertaining to skin delivery and has been central to the development of Inovio novel prototypes and designs. Her group regularly publish and have produced multiple peer-reviewed publications from projects emanating from the group and present their work in the public forum at conferences. Dr Broderick is also a co-inventor on many patents related to DNA vaccine delivery. Dr Broderick received her PhD from the University of Glasgow in Scotland and performed her post-doctoral research at the University of California, San Diego. She joined Inovio Pharmaceuticals in 2006 where she currently leads a diverse research group focused on enhanced delivery techniques for gene based therapeutics as the Senior Director, R&D.
Novel electroporation technology enhances gene delivery to the skin
Manal Saber has completed her PhD from Nottingham University. She is an associate professor of Clinical Pathology, Minia University, Egypt. She has published papers in peer reviewed journals and has been serving as an editorial board member of others.
Novel Immunotherapy for Non Hodgkin Lymphoma Using Vaccine of Cancer Cells with anti-IL-19 Antibodies